Identification of a novel therapeutic agent for Inflammatory Bowel Disease guided by systems medicine
Katie Lloyd, Stamatia Papoutsopoulou, Emily Smith, Philip Stegmaier, François Bergey, Lorna Morris, Madeleine Kittner, Hazel England, David G. Spiller, Michael White, Carrie A. Duckworth, Barry James Campbell, Vladimir Poroikov, Vítor A. P. Martins dos Santos, Alexander E Kel, , Michael David Burkitt
This study identifies clarithromycin as a potential therapeutic for inflammatory bowel disease through in-silico drug repositioning and experimental validation of its effects on NF-κB signaling.
Disease Models & Mechanisms · Sep 21, 2020Peer-reviewedSystems Biology